WO2022036049A3 - Antiviral stapled peptides against sars-cov-2 - Google Patents

Antiviral stapled peptides against sars-cov-2 Download PDF

Info

Publication number
WO2022036049A3
WO2022036049A3 PCT/US2021/045678 US2021045678W WO2022036049A3 WO 2022036049 A3 WO2022036049 A3 WO 2022036049A3 US 2021045678 W US2021045678 W US 2021045678W WO 2022036049 A3 WO2022036049 A3 WO 2022036049A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
antiviral
stapled peptides
peptides against
against sars
Prior art date
Application number
PCT/US2021/045678
Other languages
French (fr)
Other versions
WO2022036049A2 (en
Inventor
Asim Kumar Debnath
Francesca Curreli
Christopher Hillyer
Original Assignee
New York Blood Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center, Inc. filed Critical New York Blood Center, Inc.
Publication of WO2022036049A2 publication Critical patent/WO2022036049A2/en
Publication of WO2022036049A3 publication Critical patent/WO2022036049A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present specification provides stapled peptides based on the ACE2 helix for the inhibition of CARS-CoV-2 infection and methods of using them to treat COVID-19.
PCT/US2021/045678 2020-08-12 2021-08-12 Antiviral stapled peptides against sars-cov-2 WO2022036049A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063064533P 2020-08-12 2020-08-12
US63/064,533 2020-08-12

Publications (2)

Publication Number Publication Date
WO2022036049A2 WO2022036049A2 (en) 2022-02-17
WO2022036049A3 true WO2022036049A3 (en) 2022-03-24

Family

ID=80247364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/045678 WO2022036049A2 (en) 2020-08-12 2021-08-12 Antiviral stapled peptides against sars-cov-2

Country Status (1)

Country Link
WO (1) WO2022036049A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117756904B (en) * 2023-12-22 2024-05-24 潍坊医学院 Stapler peptide and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282154A1 (en) * 2003-10-06 2005-12-22 The Brigham And Women's Hospital, Inc. Angiotensin-converting enzyme-2 as a receptor for the SARS coronavirus
US20100130430A1 (en) * 2006-10-05 2010-05-27 New York Blood Center, Inc Stabilized therapeutic small helical antiviral peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282154A1 (en) * 2003-10-06 2005-12-22 The Brigham And Women's Hospital, Inc. Angiotensin-converting enzyme-2 as a receptor for the SARS coronavirus
US20100130430A1 (en) * 2006-10-05 2010-05-27 New York Blood Center, Inc Stabilized therapeutic small helical antiviral peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAN ET AL.: "Computational design of ACE2-based short peptide inhibitors of SARS-CoV-2", ACS NANO, vol. 14, no. 4, 14 April 2020 (2020-04-14), pages 5143 - 5147, XP055732485 *

Also Published As

Publication number Publication date
WO2022036049A2 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
WO2021222935A3 (en) Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
EP4249000A3 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
EP3755356A4 (en) Compositions, devices, systems, kits and methods for the treatment of a skin condition
WO2021022163A3 (en) Compounds and uses thereof
WO2005077050A3 (en) Hiv integrase inhibitors
EP3955839A4 (en) Devices, systems and methods for the treatment of abnormal tissue
EP3967321A4 (en) Use of cyclo-his-pro (chp) for preventing, ameliorating, or treating fibrosis
TW200738700A (en) HIV integrase inhibitors
EP4025256A4 (en) Compositions and methods for the treatment of viral infections
WO2021155321A3 (en) Compounds and uses thereof
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
WO2022036049A3 (en) Antiviral stapled peptides against sars-cov-2
WO2023086220A3 (en) Papd5 inhibitors and methods of use thereof
EP3893868A4 (en) Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
WO2021046634A8 (en) Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies
WO2021155316A8 (en) Compounds and uses thereof
WO2004037192A3 (en) Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
MX2021003598A (en) Microorganisms for plant pathogen inhibition.
WO2023285654A3 (en) Compounds for the treatment of covid-19
WO2023122260A3 (en) Inhibitors of sars-cov-2
WO2022115565A3 (en) Chimeric receptors and methods of use thereof
WO2022109317A9 (en) Anti-influenza antibodies and combinations thereof
MX2022010327A (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy.
WO2020185651A3 (en) Compositions and methods for treating huntington's disease
EP4335503A3 (en) Methods of treating or preventing spinal muscular atrophy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21856693

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21856693

Country of ref document: EP

Kind code of ref document: A2